SCHEMBL20173799

SCHEMBL20173799

CC(C)N1CCc2cc(C(=O)NS(=O)(=O)c3ccccc3)ccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
HDAC6 Q9UBN7 5/20 0.44
HDAC8 Q9BY41 2/20 0.44
MAPT P10636 1/20 0.44
OPRM1 P35372 1/20 0.43
OPRK1 P41145 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
P4HTM Q9NXG6 2/20 0.43
AKR1C3 P42330 1/20 0.43
BRD4 O60885 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
KCNA1 Q09470 1/20 0.41
KCNAB1 Q14722 1/20 0.41
HTT P42858 1/20 0.41
PTGER1 P34995 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119171 0.85 NPC1 (0.48) PTGS1PTGS2HDAC6HDAC8NPC1
SCHEMBL20173800 0.82 HDAC6 (0.46) HDAC6HDAC8OPRM1OPRK1NPC1
SCHEMBL20173798 0.80 HDAC6 (0.44) HDAC6HDAC8HDAC3HDAC1PTGER1
SCHEMBL25873240 0.78 POLB (0.50) HDAC6HDAC8HDAC3HDAC1HTT
SCHEMBL20173793 0.78 ALDH1A1 (0.51) HDAC6HDAC8MAPTAKR1C3LMNA
SCHEMBL21882597 0.78 RAB9A (0.41) MAPTNPC1RAB9A
SCHEMBL21882599 0.77 HDAC6 (0.43) HDAC6HDAC8MAPTOPRM1OPRK1
SCHEMBL20173805 0.77 HDAC6 (0.44) HDAC6HDAC8MAPTOPRM1OPRK1
SCHEMBL1264153 0.76 HDAC6 (0.55) HDAC6HDAC8HDAC3HDAC1
SCHEMBL20173806 0.76 OPRK1 (0.45) HDAC6HDAC8OPRM1OPRK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 PTGS1 826/4885PTGS2 1196/4885HDAC6 597/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 PTGS1 826/4885PTGS2 1196/4885HDAC6 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.